Skip to content

R&D at other companies

Eli Lilly logo
Eli LillyLLY
$3.51B+28.4%
Merck & Co. logo
Merck & Co.MRK
$12.59B+248%
Amgen logo
AmgenAMGN
$1.72B+15.7%
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
$1.54B+16.3%
EyePoint, Inc.
 logo
EyePoint, Inc. EYPT
$72.15M+23.2%
Ocular Therapeutix logo
Ocular TherapeutixOCUL
$66.21M+54.5%

Other financials

Income statement

See full
Operating income-$11.8M-14.3%
Net income-$10.9M-6.5%
EPS (diluted)-$0.46+81.7%

Balance sheet

See full
Cash & equivalents$34.4M-65.9%
Total debt$1.4M
Total equity$68.6M+7.3%
Total assets$109.8M+6.5%

Cash flow

See full
Operating cash flow-$11.6M-55.6%
CapEx$17.0K
Free cash flow-$7.1M

Valuation

See full
Market cap$96.83M+136%
Enterprise value$63.82M

Returns & leverage

See full
Return on equity-66.6%
Debt / equity
Current ratio12.2×-2.1×

Where this comes from

Reported directly by KLRS in its filing.

Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.

The official record: KLRS’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about KLRS's r&d.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is KLRS's R&D?
KLRS (KLRS) reported R&D of $7.57M in Q1 2026.
How has KLRS's R&D changed year-over-year?
KLRS's R&D increased by 25.6% year-over-year, from $6.03M to $7.57M.
What is the long-term trend for KLRS's R&D?
Over 2 years (2021 to 2025), KLRS's R&D has grown at a -49.5% compound annual growth rate (CAGR), from $120.74M to $30.75M.
What does R&D mean?
Costs of research activities to discover new knowledge and development activities to translate research into new or improved products, services, processes, or technologies.